Treatment of Ovarian & Endometrial Cancer with the Novel Folate Receptor-α-targeting Antibody Drug Conjugate, STRO-002

Time: 4:00 pm
day: Day Two

Details:

  • Optimising linker-warhead and site-specific conjugation to produce a homogeneous product and improve therapeutic index
  • Preclinical rationale for STRO-002 in cell line, xenograft and PDX studies
  • Dose-escalation study and recommended Phase 2 dose
  • Dose expansion and registration-directed clinical development studies

Speakers: